Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone

Prostate

Volumn 75, Issue 12, 2015, Pages 1329-1338

  Conteduca, Vincenza ^a   Caffo, Orazio ^b   Derosa, Lisa ^c   Veccia, Antonello ^b   Petracci, Elisabetta ^a   Chiuri, Vincenzo Emanuele ^d   Santoni, Matteo ^e   Santini, Daniele ^f   Fratino, Lucia ^g   Maines, Francesca ^b   Testoni, Sara ^a   De Giorgi, Ugo ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d VITO FAZZI HOSPITAL   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f UNIVERSITY OF ROME   (Italy)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

abiraterone acetate; cardiovascular events; castration resistant prostate cancer; metabolic syndrome; survival

Indexed keywords

ABIRATERONE; DOCETAXEL; PREDNISONE; ANDROSTANE DERIVATIVE; ENZYME INHIBITOR; STEROID 17ALPHA MONOOXYGENASE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DRUG EFFECT; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; ADULT; ANTAGONISTS AND INHIBITORS; COMPLICATION; DISEASE COURSE; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTENES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; RISK FACTORS; STEROID 17-ALPHA-HYDROXYLASE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84937510693     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23014     Document Type: Article

References (37)

1. Conteduca V, Di Lorenzo G, Bozza G, Ardito R, Aieta M,. Metabolic syndrome as a peculiar target for management of prostate cancer patients. Clin Genitourin Cancer 2013; 11: 211-220.
2. Conteduca V, Di Lorenzo G, Tartarone A, Aieta M,. The possible cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy. Crit Rev Oncol Hematol 2013; 86: 42-51.
3. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Kantoff PW,. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603.
4. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, Zajac JD, Grossmann M,. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011; 74: 377-783.
5. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C,. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
6. Keating NL, Liu PH, O'Malley AJ, Freedland SJ, Smith MR,. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014; 65: 4816-4824.
7. Koren-Morag N, Goldbourt U, Tanne D,. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: A prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005; 36: 1366-1371.
8. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR,. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250.
9. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT,. Metabolic syndrome and the risk of prostate cancer in Finnish men: A population-based study. Cancer Epidemiol Biomarkers Prev 2004; 13: 1646-1650.
10. Lund Håheim L, Wisløff TF, Holme I, Nafstad P,. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006; 164: 769-774.
11. Pollak M,. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
12. LeRoith D, Roberts CT, Jr,. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127-137.
13. Faris JE, Smith MR,. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 2010; 17: 240-246.
14. Saylor PJ, Smith MR,. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. J Urol 2009; 181: 1998-2008.
15. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS,. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86: 4261-4267.
16. Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS,. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002; 56: 779-786.
17. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S,. Metabolic syndrome in men with prostate cancer undergoing long-term androgen deprivation therapy. J Clin Oncol 2006; 24: 3979-3983.
18. Smith MR, Lee H, Nathan DM,. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-1308.
19. Flanagan J, Gray PK, Hahn N, Hayes J, Myers LJ, Carney-Doebbeling C, Sweeney CJ,. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol 2011; 22: 801-807.
20. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, Chan JM, Anast JW, Carroll PR, Kane CJ,. Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. Urology 2005; 66: 1060-1065.
21. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR,. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007; 109: 1192-1202.
22. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG,. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004; 22: 439-445.
23. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM,. Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
24. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM,. De Bono JS; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992.
25. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
26. Alberti KG, Zimmet PZ,. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus: Provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
27. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD,. Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the treating to new targets study. Lancet 2006; 368: 919-928.
28. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M,. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
29. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J,. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
30. Gerstenbluth RE, Seftel AD, Hampel N, Oefelein MG, Resnick MI,. The accuracy of the increased prostate specific antigen level (greater than or equal to 20ng /ml.) in predicting prostate cancer: Is biopsy always required?. J Urol 2002; 168: 1990-1993.
31. The criteria committee of the new york heart association: Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 9th ed. Boston: Little, Brown & Co 1994; pp. 253-256.
32. Mulders PF, Molina A, Marberger M, Saad F, Higano CS, Chi KN, Li J, Kheoh T, Haqq CM2, Fizazi K,. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol 2014; 65: 875-883.
33. Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, De Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ,. Abiraterone Global EAP Investigators. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: Final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol 2014; 15: 1263-1268.
34. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW,. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 2008; 299: 289-295.
35. Nanda AN, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV,. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009; 302: 866-873.
36. Nguyen PL, Je Y, Schutz FAB, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK,. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer a meta-analysis of randomized trials. JAMA 2011; 306: 2359-2366.
37. Pezaro C, Mukherji D, Tunariu N, Cassidy AM, Omlin A, Bianchini D, Seed G, Reid AH, Olmos D, de Bono JS, Attard G,. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration resistant prostate cancer. Br J Cancer 2013; 109: 325-331.